20:02 , Nov 2, 2018 |  BC Week In Review  |  Financial News

With clear FDA path, Clementia raises $70.2M

Days after revealing regulatory plans for its therapy for a rare bone disease, Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) raised $70.2 million in a bumped-up follow-on offering. Clementia priced 5.3 million shares at $13.25 late Oct. 29,...
14:43 , Oct 30, 2018 |  BC Extra  |  Financial News

With clear FDA path, Clementia raises $70.2M

Days after revealing regulatory plans for its therapy for a rare bone disease, Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) raised $70.2 million in a bumped-up follow-on offering. Clementia priced 5.3 million shares at $13.25 late Monday, hours...
22:55 , Oct 25, 2018 |  BC Innovations  |  Targets & Mechanisms

Blueprint for selectivity

Blueprint Medicines Corp. is making the jump from cancer to rare disease with an inhibitor for the rare pediatric bone disease FOP that sets the company up against at least two competitors further ahead in...
19:27 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Blueprint debuts selective ALK2 inhibitor for rare musculoskeletal disease

Blueprint Medicines Corp. (NASDAQ:BPMC) provided the first glimpse of its preclinical ALK2 inhibitor program, BLU-782, when it presented data at the American Society for Bone and Mineral Research (ASBMR) meeting in Montreal on Sept. 30....
15:30 , Sep 30, 2018 |  BC Extra  |  Preclinical News

Blueprint Medicines unveils preclinical data for rare bone disease program

Blueprint Medicines Corp. (NASDAQ:BPMC) provided the first glimpse of its preclinical ALK2 inhibitor program, BLU-782, when it presented data at the American Society for Bone and Mineral Research (ASBMR) meeting in Montreal on Sunday. Blueprint...
19:43 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps...
15:47 , Aug 30, 2018 |  BC Extra  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps...
03:00 , Aug 10, 2018 |  BC Innovations  |  Targets & Mechanisms

Getting to function

A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication....
20:06 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting activin signaling could enhance the efficacy of platinum-based chemotherapy in KRAS-mutant lung cancer. In 59 patients with stage IV non-small cell lung cancer...
04:15 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...